Disease & disorder

ALG12-congenital disorder of glycosylation

MONDO:0011783

A form of congenital disorders of N-linked glycosylation characterized by facial dysmorphism (prominent forehead, large ears, thin upper lip), generalized hypotonia, feeding difficulties, moderate to severe developmental delay, progressive microcephaly, frequent upper respiratory tract infections due to impaired immunity with decreased immunoglobulin levels, and decreased coagulation factors. Additional features include hypogonadism with or without hypospadias in males, skeletal anomalies, seizures and cardiac anomalies in some cases. The disease is caused by loss of function mutations of the gene ALG12 (22q13.33).

Clinical trials0
Recruiting0
Drug concepts studied0
Synonyms13

Research intelligence

Directly mapped studies only · unique clinical trials

Current registry observations. Phase counts may overlap. Study start dates are not registry registration dates. Investigational interventions are not approved-treatment recommendations.

Medications under investigation

Verified disease and drug mappings that co-occur within the same study; not evidence of effectiveness.

Loading mapped interventions…

MONDO disease family

Loading verified ontology relationships…

Recruiting studies by city

Loading research-site locations…

Trial status

Loading…

Trial phase

Loading…

Study start year

Loading…

Investigated drug interventions

Loading…

Drugs being studied

Disease identity and terminology: MONDO. Trial relationships: ClinicalTrials.gov.